XML 43 R14.htm IDEA: XBRL DOCUMENT
v3.24.1.1.u2

Long-term Investments, Net | 12 Months Ended
--- | ---
Feb. 29, 2024
Equity Method Investments and Joint Ventures [Abstract] |
Long-term Investments, Net | 7. LONG-TERM INVESTMENTS, NET The investments as of February 28, 2023 and February 29, 2024 were as follows:
|  | As of |
|  | February 28, 2023 |  |  | February 29, 2024 |
|  | RMB |  |  | RMB |  |  | USD |
Equity-method investments: |  |  |  |  |  |  |  |  |
- FSOL |  |  | — |  |  |  | — |  |  |  | — |
- Shanghai Yanjin Information Technology Co., Ltd. ("VIP Sing") |  |  | — |  |  |  | — |  |  |  | — |
- Others |  |  | — |  |  |  | — |  |  |  | — |
Equity investments without readily determinable fair values: |  |  |  |  |  |  |  |  |
- Huangshan Xingyue Research Travel Education Co., Ltd. (“Huangshan”) |  |  | 500 |  |  |  | — |  |  |  | — |
- Nanjing Chengwei Venture Capital Partnership (Limited Partnership) (“Chengwei”) |  |  | 27,000 |  |  |  | 36,000 |  |  |  | 5,002 |
Total |  |  | 27,500 |  |  |  | 36,000 |  |  |  | 5,002 |
The Group purchased 2,564,103 Series B preferred shares and 1,923,077 Series B-2 preferred shares of FSOL in March and April 2020, respectively, with the total cash consideration of US$5,833 to acquire approximately 35.77% of FSOL. The Group accounted for the investment in FSOL under equity-method as the preferred shares were deemed in-substance common stocks and the Group has the ability to exert significant influence. The Group recognized investment income of RMB 460, nil and nil from equity method investments for the years ended February 28, 2022, 2023 and February 29, 2024, respectively. The investment was fully impaired for RMB 35,332 in the year ended February 28, 2022. The Group purchased 8.1% equity interest of Shanghai Yanjin Information Technology Co., Ltd. ("VIP Sing") in May 2020 with cash consideration of RMB 3,000. The Group accounted for the investment in VIP Sing under equity-method as the Group has the ability to exert significant influence through the board seat held by the Group. The Group recognized investment loss of RMB 1,522, nil and nil from equity method investments for the years ended February 28, 2022, 2023 and February 29, 2024. The investment was fully impaired for RMB 252 in the year ended February 28, 2022. In January 2022, the Group purchased 15% equity interest of Huangshan with consideration of RMB 500. In December 2021, February 2022, August 2022 and May 2023, the Group paid considerations of RMB 4,500, RMB 9,000, RMB 13,500 and RMB 9,000 to purchase equity interest of Chengwei, and the equity interest held by the Group as of February 29, 2024 was 4.01%. The Group also committed to provide further capital investment to Chengwei of RMB 9,000 (US$1,250) when requested by Chengwei in future. The Group accounted the investment in Huangshan and Chengwei under equity investments without readily determinable fair values method as the Group had no significant influence over the investee and Huangshan and Chengwei had no readily determinable fair value. The investment in Huangshan was fully impaired for RMB 500 (US$69) in the year ended February 29, 2024.

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 323 -SubTopic 740 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481543/323-740-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 323 -Publisher FASB -URI https://asc.fasb.org//323/tableOfContent + Details
Name: | us-gaap_EquityMethodInvestmentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration